Skip to main content

Green Eric Mark's Form 4/A amendment

Amended

West Pharmaceutical Services IncWST · filed Aug 8, 2024

Accession no.
0001127602-24-021890
Filed
Aug 8, 2024
Trade date
May 7, 2024
Filing delay
93 days
Rule 10b5-1 plan
Checked
Original filed
May 9, 2024

This filing lists 7 non-derivative transactions and 4 derivative transactions. Open-market sales total $24.2M. It was filed 93 days after the trade.

This amendment replaces 0001127602-24-014765 (filed May 9, 2024).

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Green Eric MarkCIK 0001336007Director, Officer (President, CEO and Board Chair)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 7, 2024Common StockMOption exerciseAcquired+9,316$57.38+$534,552.08162,224.12Direct
May 7, 2024Common StockMOption exerciseAcquired+15,684$57.38+$899,947.92177,908.12Direct
May 7, 2024Common StockMOption exerciseAcquired+41,000$59.64+$2,445,240218,908.12Direct
May 7, 2024Common StockSSaleDisposed−9,316$366.64F2−$3,415,618.24209,952.12Direct
May 7, 2024Common StockSSaleDisposed−15,684$366.66F2−$5,750,695.44193,908.12Direct
May 7, 2024Common StockSSaleDisposed−41,000$366.65F2−$15,032,650152,908.12Direct
May 7, 2024Common StockMOption exerciseAcquired+9,000$59.64+$536,760161,908.12Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
May 7, 2024Common StockMOption exerciseDisposed−9,316$0.00$00Direct
May 7, 2024Common StockMOption exerciseDisposed−15,684$0.00$00Direct
May 7, 2024Common StockMOption exerciseDisposed−41,000$0.00$045,732Direct
May 7, 2024Common StockMOption exerciseDisposed−9,000$0.00$036,732Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in either 2025 or 2026, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023.

F2

The price reported in Column 4 is a weighted average price.

Referenced by the price of 3 transactions in Table I.

Remarks

The only change to this form filed on 5/9/2024 is that the Rule 10b5-1(c) box is now checked.

Read the full filing on SEC EDGAR (opens in a new tab)